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Abstract. A series of forty four 4-aminopiperidine derivatives was screened in vitro against 16 
four protozoan parasites (Trypanosoma brucei rhodesiense, Trypanosoma cruzi, 17 
Leishmania donovani, and Plasmodium falciparum). This screening identified 29 molecules 18 
selectively active against bloodstream form T. b. rhodesiense trypomastigotes with IC50 19 
values ranging from 0.12 to 10 µM, and 33 compounds active against the 20 
chloroquine/pyrimethamine resistant K1 strain of P. falciparum in the range 0.17 to 5 µM. 21 
In addition, seven compounds displayed activity against intracellular T. cruzi amastigotes, 22 
in the same range as the reference drug benznidazole (IC50 = 1.97 µM), but were also 23 
cytotoxic to L6-cells showing little selectivity for T. cruzi. None of the molecules tested 24 
showed interesting antileishmanial activity against axenic amastigotes of L. donovani. To 25 
our knowledge, this is the first report of the antitrypanosomal activity of molecules bearing 26 
the 4-aminopiperidine skeleton. 27 
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INTRODUCTION 33 
Tropical diseases caused by parasitic protozoa are a cause of great mortality and 34 
disability in the less developed world. Malaria and kinetoplastid diseases such as human 35 
African trypanosomiasis (HAT or sleeping sickness), Chagas’ disease and leishmaniases 36 
are among the main neglected parasitic diseases affecting hundred millions of people 37 
worldwide (1). However, the low income of affected population does not make it 38 
financially attractive for pharmaceutical companies to make the investment in the 39 
development of  new drugs against these diseases. The number of the available 40 
antiprotozoal drugs is limited and they are old, toxic and losing efficacy due to the 41 
emergence of resistant parasites. New drugs are thus urgently needed (39). 42 
The landscape of drug discovery and development for new anti-parasitic drugs 43 
changed in the last few years thanks to the financial backing from not-for-profit 44 
organizations and the involvement of public-private partnerships. The collaboration of 45 
different pharmaceutical companies with the Special Programme for Research and Training 46 
in Tropical Diseases (TDR), giving access to their compound library to help search for new 47 
anti-parasitic drugs, is a good example of the pragmatic approach required for the 48 
development of new medicaments for those neglected diseases (2, 17, 34).  The discovery 49 
of new hit and lead compounds against protozoan parasites by screening compound 50 
libraries has been used very efficiently in our group for the last few years. Very potent 51 
antiprotozoal compounds active in vitro and in vivo against T. b. rhodesiense and P. 52 
falciparum, were identified by our group (18, 19, 40). These lead compounds were 53 
discovered by screening against T. brucei and P. falciparum a small library (< 100 54 
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molecules) of dicationic compounds structurally related to known anti-parasitic drugs (e.g. 55 
pentamidine, diminazene) but primarily synthesized by us for different medicinal targets.  56 
Following this successful approach, we now have selected from our in-house 57 
compound collection another series of polyamines molecules that possess the 1-phenethyl-58 
4-aminopiperidine skeleton (Fig. 1). These molecules were anticipated to display 59 
antiprotozoal activity because they are structurally related to the known antitrypanosomal 60 
alkylpolyamines MDL27695 (9, 24), CHE-3-7-3 (7), BW-1 (44) and particularly to the 4-61 
aminopiperidine based antimalarial agents described recently by Ellman and co-workers 62 
(10, 11). To test this hypothesis, forty four 1-phenethyl-4-aminopiperidine derivatives were 63 
tested in vitro against four protozoan parasites responsible for HAT (T. brucei rhodesiense), 64 
Chagas’ disease (T. cruzi), visceral leishmaniasis (L. donovani) and malaria (P. 65 
falciparum). Two compounds found to be active in vitro (IC50 < 0.2 µM) and displaying an 66 
acceptable selectivity towards the parasites (SI > 100)
1
 were subjected to in vivo assays in 67 
mouse models of acute HAT (T. b. brucei) or malaria (P. berghei).  68 
                                                 
1
 Selectivity index (SI) is defined as the ratio: IC50 (L6-cells) / IC50 (parasite) 
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Fig.1. General structure of 1-phenethyl-4-aminopiperidine derivatives screened in this 70 
study and known alkylpolyamine analogues with antiprotozoal activity.   71 
 72 
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MATERIAL AND METHODS.  77 
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Fig. 2. Structure and synthesis protocol for the compounds screened against T. brucei, T. 79 
cruzi, L. donovani and P. falciparum. 80 
 81 
Chemistry. All of the compounds were synthesised following the procedures previously 82 
reported by us (20-22) and tested against the clinically relevant stages of four different 83 
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parasites: T. b. rhodesiense trypomastigotes, T. cruzi amastigotes, L. donovani amastigotes 84 
and erythrocytic P. falciparum. Compounds 3a-3i, 5a-5i, 8, 9 and 12 were tested in vitro as 85 
their trifluoroacetate salts. Compound 5h was administered in vivo as its dihydrochloride 86 
salt (MW = 516.59 g/mol) which was obtained in 72% yield from the trifluoroacetate salt 87 
derivative using a strongly basic anion exchange resin (Amberlite IRA400) in the HCl 88 
form. 89 
Biological assays.  90 
(i) Cultivation of parasites, in vitro activity and cytotoxicity: For all the susceptibility 91 
assays against the parasites and cells, each drug was tested in duplicate and each assay was 92 
repeated at least once. 93 
a) Activity against Trypanosoma brucei rhodesiense STIB900. This stock was isolated in 94 
1982 from a human patient in Tanzania and after several mouse passages cloned and 95 
adapted to axenic culture conditions (6, 43). Minimum Essential Medium (50 µl) 96 
supplemented with 25 mM HEPES, 1g/l additional glucose, 1% MEM non-essential amino 97 
acids (100x), 0.2 mM 2-mercaptoethanol, 1mM Na-pyruvate and 15% heat inactivated 98 
horse serum was added to each well of a 96-well microtiter plate. Seven 3-fold dilutions 99 
were used covering a range from 90 to 0.123 µg/ml. Then 10
4
 bloodstream forms of T. b. 100 
rhodesiense STIB 900 in 50 µl was added to each well and the plate incubated at 37 °C 101 
under a 5 % CO2 atmosphere for 72 h. 10 µl Alamar Blue (resazurin, 12.5 mg in 100 ml 102 
double-distilled water)
 
was then added to each well and incubation continued for a further 103 
2–4 h (37). Then the plates were read with a Spectramax Gemini XS microplate 104 
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation 105 
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wave length of 536 nm and an emission wave length of 588 nm. Data were analyzed using 106 
the microplate reader software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, 107 
CA, USA).  108 
b) Activity against T. cruzi. Rat skeletal myoblasts (L-6 cells) were seeded in 96-well 109 
microtitre plates at 2000 cells/well in 100 µL RPMI 1640 medium with 10% FBS and 110 
2 mM l-glutamine. After 24 h the medium was removed and replaced by 100 µl per well 111 
containing 5000 trypomastigote forms of T. cruzi Tulahuen strain C2C4 containing the β-112 
galactosidase (Lac Z) gene (12). After 48 h the medium was removed from the wells and 113 
replaced by 100 µl fresh medium with or without a serial drug dilution. Seven 3-fold 114 
dilutions were used covering a range from 90 to 0.123 µg/ml. After 96 h of incubation the 115 
plates were inspected under an inverted microscope to assure growth of the controls and 116 
sterility. Then the substrate CPRG/Nonidet (50 µl) was added to all wells. A color reaction 117 
developed within 2–6 h and could be read photometrically at 540 nm. Data were transferred 118 
into the graphic programme Softmax Pro (Molecular Devices), which calculated IC50 119 
values. 120 
c) Activity against L. donovani. Amastigotes of L. donovani strain MHOM/ET/67/L82 were 121 
grown in axenic culture at 37 °C in SM medium (16) at pH 5.4 supplemented with 10% 122 
heat-inactivated fetal bovine serum under an atmosphere of 5% CO2 in air. One hundred 123 
microlitres of culture medium with 10
5
 amastigotes from axenic culture with or without a 124 
serial drug dilution were seeded in 96-well microtitre plates. Seven 3-fold dilutions were 125 
used covering a range from 30 to 0.041 µg/ml. After 72 h of incubation the plates were 126 
inspected under an inverted microscope to assure growth of the controls and sterile 127 
conditions. 10 µl of Alamar Blue (12.5 mg resazurin dissolved in 100 ml distilled water) 128 
 9 
(32) were then added to each well and the plates incubated for another 2 h. Then the plates 129 
were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices 130 
Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an 131 
emission wave length of 588 nm. Data were analyzed using the software Softmax Pro 132 
(Molecular Devices Cooperation, Sunnyvale, CA, USA). Decrease of fluorescence 133 
(= inhibition) was expressed as percentage of the fluorescence of control cultures and 134 
plotted against the drug concentrations. From the sigmoidal inhibition curves the IC50 135 
values were calculated. 136 
d) Activity against P. falciparum. In vitro activity against erythrocytic stages of P. 137 
falciparum was determined using a 
3
H-hypoxanthine incorporation assay (23, 31), using the 138 
chloroquine and pyrimethamine resistant K1 strain that originate from Thailand (42) and 139 
the standard drug chloroquine (Sigma C6628). Compounds were dissolved in DMSO at 10 140 
mg/ml and added to parasite cultures incubated in RPMI 1640 medium without 141 
hypoxanthine, supplemented with HEPES (5.94 g/l), NaHCO3 (2.1 g/l), neomycin (100 142 
U/ml), Albumax
R
 (5 g/l) and washed human red cells A
+
 at 2.5% haematocrit (0.3% 143 
parasitaemia). Seven 2-fold dilutions were used covering a range from of 5 to 0.156 µg/ml. 144 
The 96-well plates were incubated in a humidified atmosphere at 37 °C; 4% CO2, 3% O2, 145 
93% N2. After 48 h 50 µl of 
3
H-hypoxanthine (=0.5 µCi) was added to each well of the 146 
plate. The plates were incubated for a further 24 h under the same conditions. The plates 147 
were then harvested with a Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and 148 
the red blood cells transferred onto a glass fibre filter then washed with distilled water. The 149 
dried filters were inserted into a plastic foil with 10 ml of scintillation fluid, and counted in 150 
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a Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 values were 151 
calculated from sigmoidal inhibition curves using Microsoft Excel. 152 
e) In vitro cytotoxicity with L-6 cells. Assays were performed in 96-well microtiter plates, 153 
each well containing 100 µl of RPMI 1640 medium supplemented with 1% L-glutamine 154 
(200mM) and 10% fetal bovine serum, and 4 x 10
 4
 L-6 cells (a primary cell line derived 155 
from rat skeletal myoblasts). Seven 3-fold dilutions were used covering a range from 90 to 156 
0.123 µg/ml. After 72hours of incubation the plates were inspected under an inverted 157 
microscope to assure growth of the controls and sterile conditions. 10µl of Alamar Blue 158 
was then added to each well and the plates incubated for another 2 hours. Then the plates 159 
were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices 160 
Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an 161 
emission wave length of 588 nm. Data were analysed using the microplate reader software 162 
Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). 163 
(ii) In vivo activity: 164 
a) In vivo antiplasmodial efficacy. All efficacy studies were approved by the veterinary 165 
authorities of the local government (Canton Basel, Switzerland). In vivo antimalarial 166 
activity was assessed basically as previously described (36). Groups of three female NMRI 167 
mice (20–22 g) intravenously infected with 2 x 10
7
 parasitized erythrocytes on day 0 with 168 
the GFP-transfected P. berghei strain ANKA (26). Compound 5h was formulated in 100% 169 
DMSO at 10 mg/ml (C = 19.36 mM), diluted 10-fold in distilled water and administered 170 
intraperitoneally 
 
(on four consecutive days 4, 24, 48 and 72 h post infection) in a volume 171 
of 10 ml kg
-1
 (i.e., 10 mg kg
-1
). Parasitemia was determined on day 4 post infection (24h 172 
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after last treatment) by FACS analysis. Activity was calculated as the difference between 173 
the mean per cent parasitaemia for the control (n = 5 mice) and the treated groups expressed 174 
as a per cent relative to the control group. The survival time in days was also recorded up to 175 
30 days after infection. A compound was considered curative if the animal survived to day 176 
30 after infection with no detectable parasites. 177 
 178 
b) In vivo efficacy against T. brucei. Female NMRI mice weighting 22–25 g were 179 
infected with cryopreserved stabilates of T. brucei brucei STIB 795 (derivative of strain 180 
427 originally isolated from a Glossina pallidipes in Uganda in 1960. After passages in a 181 
sheep, a tsetse fly and several passages in mice, a clone was adapted to axenic in vitro 182 
culture) (43). Each mouse was injected intraperitoneally (ip) with 1×10
5
 (STIB 795) 183 
bloodstream forms. Groups of four mice were treated with the compound at 50 mg/kg ip on 184 
days 3, 4, 5, and 6 post-infection. A control group remained untreated. The parasitemia of 185 
all animals was checked every second day up to day 14 post-infection and two times a week 186 
thereafter until 60 days. Death of animals was recorded to calculate the mean survival time. 187 
Surviving and aparasitemic mice were considered cured at 60 days and then euthanized. 188 
  189 
RESULTS AND DISCUSSION 190 
1. In vitro activity against T. brucei rhodesiense.  The results of the in vitro activity are 191 
shown in Table 1. Twenty nine out of 44 molecules showed activity against trypomastigote 192 
bloodstream forms of T. b. rhodesiense with an IC50 < 10 µM. Seven derivatives in 193 
particular displayed IC50 < 1 µM and were selective for the parasite (1e, 1f, 1g, 1h, 1i, 5i 194 
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and 6). The best activity in vitro was observed for the tert-butoxycarbonyl-substituted 8-195 
carbon chain derivative 1g (IC50 = 0.119 µM, SI = 130).  196 
Interestingly, the most active compounds, except 5i, had the alkane structure 1, where the 197 
R1 position on the piperidine 4-amino group remains unsubstituted (R1 = H). This suggests 198 
that the substitution of this amine by a propionyl group (R1 = COEt) is detrimental to the 199 
antitrypanosomal activity for this series. The same trend was observed with the aromatic 200 
derivative 6 which was 30-fold more active than its propionamide derivative 7. This may 201 
indicate that the presence of an H-bond donating group or a basic nitrogen atom in this 202 
position is critical for anti-T. brucei activity.   203 
The polyamine metabolic pathway which is present in most eukaryotes including the 204 
majority of protozoa has been explored as a possible target for chemotherapy in the last 25 205 
years because endogenous polyamines (i.e., putrescine, spermidine and spermine) are 206 
necessary for cellular growth and proliferation (38). The most successful example of this 207 
approach is represented by α-difluoromethylornithine (DFMO), a suicide inhibitor of 208 
ornithine decarboxylase (ODC) that was registered for the treatment of late-stage 209 
gambiense sleeping sickness in the 1990s (15). S-Adenosylmethionine decarboxylase 210 
(AdoMetDC) and spermidine synthase (SpdSyn), the other enzymes of the T. brucei 211 
polyamine biosynthetic pathway (33), have also been  proposed as potential therapeutic 212 
targets (27, 28). On the other hand, enzymes of the trypanothione metabolism such as 213 
trypanothione reductase (TR) and trypanothione synthase (TS) have also been validated as 214 
drug targets against trypanosomes (5, 14, 41). Trypanothione is a distinctive spermidine-215 
glutathione conjugate synthesised by trypanosomes and used as antioxidant mechanism in a 216 
similar way as glutathione in mammalians cells (25). The higher activity observed with the 217 
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derivatives (1e-1i) where the R1 position on the piperidine 4-amino group remains 218 
unsubstituted (i.e., secondary amino group, R1 = H) is compatible with a mechanism of 219 
action involving compounds able to mimic spermidine. In fact, the secondary amino group 220 
of these compounds may be protonated at physiological pH and mimic the positively 221 
charged central NH group of spermidine. Accordingly, reduced activity was observed with 222 
the propionamide derivatives that would not be protonated at physiological pH due to the 223 
reduced basicity of the propionamide nitrogen. Thus, it is possible that the 224 
antitrypanosomal activity of compounds 1e-1i relates to their inhibition of trypanothione 225 
reductase (TR), the enzyme responsible for maintaining the intracellular redox balance in 226 
trypanosomes by regenerating trypanothione disulfide [T(S)2] to its reduced state [T(SH)2] 227 
(30). Work to test this hypothesis is currently ongoing and shall be reported in due course.  228 
 229 
2. In vitro activity against P. falciparum. The compounds were tested against the K1 230 
strain of P. falciparum which is resistant to the malaria drugs chloroquine and 231 
pyrimethamine (Table 1). Thirty three compounds showed some activity against P. 232 
falciparum (IC50 < 5 µM) among which thirteen (1e-1i, 4e, 4g, 4i and 5e-5i) displayed low 233 
micromolar IC50 in the range 0.17 – 0.91 µM. Most of these compounds were not very 234 
specific, showing low SI values from 16 to 83. However, two compounds, 5g and 5h, were 235 
fairly selective for the parasite, being 5h the most active and selective compound of the 236 
series (IC50 = 0.17 µM, SI = 558). This IC50 value was similar to that of the reference drug 237 
chloroquine in this assay (0.172 µM). Interestingly, six of the molecules showing the best 238 
activities against P. falciparum (1e, 1f, 1g, 1h and 1i) also displayed the best anti-T. brucei 239 
action (Table 1).  240 
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Overall, the safety profile of the antimalarial hit compounds presented here (SI in the range 241 
16 to 558) was superior to that of the 4-aminopiperidines based compounds described by 242 
Ellman and co-workers for the same range of activity against chloroquine-resistant strains 243 
of P. falciparum (11). The hit 5h showed the same potency as chloroquine (IC50 = 0.17 244 
µM)  against the chloroquine/pyrimethamine resistant strain K1 with a SI of 558. As a 245 
whole, the results of antiplasmodial activity were consistent with the SAR observed by 246 
Ellman (10, 11); thus, the presence of a basic amine in the linker was important and the 247 
acylation of this group resulted in a drop in potency (compare 1a-1i vs 2a-2i). Nevertheless, 248 
the most potent and selective compounds (5g, 5h and 5i) bear acylated amines. This 249 
apparent contradiction may be explained by the presence of the guanidinium moiety since 250 
basic groups, potentially protonated at intracellular pH, are thought to be important for the 251 
uptake and concentration of this kind of antimalarial compounds into the acidic food 252 
vacuole (29).  253 
Another interesting feature regarding the SAR of these polyamine compounds was the 254 
correlation observed between antimalarial activity and increasing methylene chain length 255 
for 1d-1i,  4a-4i, and 5a-5i. A series of methylene chain bisguanidinium analogues 13-15 256 
previously synthesised by us (22) and structurally related to 5e, 5g, and 5h, respectively, 257 
were also evaluated against this parasite, revealing a similar trend (Table 2). In 258 
consequence, the antimalarial activity of the compounds may be related to their 259 
lipophilicity and the selective uptake by infected red blood cells (RBC). A similar pattern 260 
was observed previously by Edwards et al. (16) for a series of α,ω-dibenzyltetraamines 261 
analogues of MDL27695 (Fig. 1), the activity of which correlated with selective uptake by 262 
RBC. The authors postulated that the accumulation in RBC may be related to the 263 
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lipophilicity of the compounds (24). On the other hand, Calas et al. have shown a positive 264 
relationship between the abilities of  long methylene chain mono- and bis-quaternary 265 
ammonium salts to inhibit P. falciparum growth in vitro and their inhibition of 266 
phosphatidylcholine biosynthesis (3, 4). Recent report by that group on the antimalarial 267 
activity of 12- and 16-methylene chain bis-cationic compounds mimicking the structure of 268 
choline and structurally related to compounds 13-15 (e.g., bis-amidines, bis-guanidines) 269 
points also to a similar mechanism of action involving the inhibition of the phospholipid-270 
related choline carrier (13). Compounds that mimick the structure of choline, the major 271 
malarial phospholipid necessary for the de novo biosynthesis of phosphatidylcholine, are 272 
potential substrates for the parasite choline carrier (8). Thus, the methylene (di)cationic lead 273 
compounds (13–15) and the piperidine derivatives 5e–5i (assuming that the piperidinyl 274 
nitrogen atom is charged at physiological pH) might possibly interfere with the parasite 275 
choline transporter as reported earlier for structurally related compounds bearing two polar 276 
heads separated by a methylene spacer (13). However, this hypothesis would need 277 
experimental confirmation. 278 
 279 
3. In vitro activity against L. donovani and T. cruzi. None of the 1-phenethyl-4-280 
aminopiperidine derivatives screened in this study showed significant activity in vitro 281 
against axenic L. donovani amastigotes. There is no clear explanation for the lack of 282 
activity against axenic L. donovani. However, the low pH of the culture medium (pH 5.4) 283 
which corresponds to the pH of the phagolysosome may reduce diffusion across the 284 
parasite’s membrane of these basic amino compounds that would be charged at this pH (35) 285 
and therefore  would not reach their intracellular target. 286 
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On the other hand, seven compounds (1g-i, 2f, 2i, 4i, and 5i) showed notable activity  (i.e., 287 
IC50 < 10 µM) against intracellular T. cruzi amastigotes in the range of the reference drug 288 
benznidazole (1.97 µM). However, these compounds were not selective (SI < 3), being 289 
cytotoxic to L6-cells.  290 
 291 
4. In vivo activity.  Two compounds, 1g and 5h, were subjected to in vivo assays in mouse 292 
model of acute HAT (T. b. brucei) and malaria (P. berghei) infection, respectively. Both 293 
compounds were chosen because they fulfilled the “hit criteria” of  activity and selectivity  294 
against P. falciparum K1 and T. b. rhodesiense STIB900 (i.e., IC50 < 0.2 µg/ ml; SI > 100) 295 
as defined by the drug screening network of the Special Programme for Research and 296 
Training in Tropical Diseases (WHO-TDR) (34).  297 
To detect a possible in vivo effect of 1g, the compound was first tested against STIB795, a  298 
mouse model that has proven to be relatively easy to cure by trypanocides such as 299 
pentamidine or diminazene. However, since the intraperitoneal injection of 1g (4×50 300 
mg/kg) to mice infected with T. b. brucei (STIB795) did not extend the survival of the 301 
animals, the compound was not tested further in the more difficult to cure STIB900 mouse 302 
model. On the other hand, compound 5h appeared to be toxic after the first application of 303 
50mg/kg to mice infected with P. berghei. Application of a lower dose of 5h (4×10 mg/kg) 304 
produced no activity in this murine model of malaria infection. The lack of in vivo activity 305 
of 1g and 5h may possibly be explained by unfavourable pharmacokinetic properties of the 306 
compounds. 307 
 308 
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Conclusion 309 
The screening of an in-house collection of 4-aminopiperidine analogues allowed the 310 
discovery of several compounds with submicromolar activity in vitro against a 311 
chloroquine/pyrimethamine resistant strain of P. falciparum, and T. b. rhodesiense, 312 
respectively. Interestingly, these compounds displayed higher selectivity indices as 313 
compared to the antimalarial  4-aminopiperidine derivatives described by Ellman and co-314 
workers (10, 11). However, 1g and 5h, the two compounds that were selected and tested in 315 
murine models of sleeping sickness and malaria, respectively, showed no activity in vivo. 316 
Poor pharmacokinetics may possibly account for the lack of in vivo efficacy of these 317 
compounds.  Further investigations are ongoing to determine the possible targets of the 318 
antitrypanosomal hit compounds. 319 
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Table 1. In Vitro Antiprotozoal Activity of 4-Aminopiperidine Derivatives 470 
Cmpd T. b. rhod.a T. cruzib L. donov.c P. falc.d Cytox. L6e 
 IC-50 (µM) (Selectivity index)f 
Ref. drug Melarsoprol 
0.0075 
Benznidazole 
1.97 
Miltefosine 
0.205 
Chloroquine 
0.172g 
 
1a 25.637 55.48 81.20 2.06 173.72 
1b 8.643 55.37 68.94 2.08 128.55 
1c 10.933 56.27 > 80 1.28 154.81 
1d 8.733 68.97 > 77 1.53 95.60 
1e 0.790 (36) 28.59 > 74 0.90 (43) 39.34 
1f 0.289 (41) 11.94 > 72 0.77 (42) 32.87 
1g 0.119 (130) 5.72 > 69 0.62 (25) 15.53 
1h 0.126 (48) 3.73 > 67 0.36 (16) 6.05 
1i 0.156 (52) 3.16 17.82 0.32 (25) 8.20 
2a 65.643 >68 > 68 5.07 > 204 
2b 52.084 > 66 > 66 2.83 > 198 
2c 16.659 > 69 > 69 2.54 156.63 
2e 6.427 > 65 47.31 3.20 130.01 
2f 3.742 9.93 19.28 1.00 33.74 
2g 3.943 24.17 23.37 1.54 30.55 
2h 5.968 11.68 34.83 1.43 16.01 
2i 4.070 8.07 6.20 1.32 13.75 
3a 61.507 > 56 > 56 > 9.42 > 204 
3b 34.881 > 55 > 55 > 9.17 > 165 
3c 76.977 > 53 > 53 > 8.94 > 161 
3d 21.239 > 52 6.49 > 8.73 > 157 
3e 6.320 > 51 > 51 > 8.52 > 153 
3f 4.775 > 49 > 49 > 8.32 > 149 
3g 4.081 > 48 > 48 > 8.13 138.13 
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3h 3.046 > 47 > 47 > 7.97 129.94 
3i 1.247 29.55 13.68 3.64 20.87 
4a 4.092 36.77 19.10 1.85 35.63 
4b 7.603 > 53 31.04 1.35 80.67 
4e 2.379 23.16 13.23 0.85 (29) 24.89 
4g 1.590 12.29 14.81 0.60 (35) 21.51 
4i 1.257 5.20 5.78 0.41 (18) 7.54 
5a 54.677 > 52 22.76 3.91 > 157 
5c 129.667 > 49 23.02 3.18 > 149 
5e 2.925 > 47 39.66 0.80 (83) 104.76 
5f 14.068 > 46 32.15 0.91 (>152) > 139 
5g 6.836 > 45 18.74 0.31 (222) 69.09 
5h 3.748 > 44 14.85 0.17 (558) 94.87 
5i 0.431 (24) 6.90 10.37 0.21 (50) 10.61 
6 0.503 (219) 17.30 78.11 1.66 110.62 
7 15.140 41.03 > 79 5.87 128.07 
8 9.270 > 49 > 49 > 8.24 > 148 
9 98.813 > 56 > 56 2.49 > 168 
10 21.280 46.15 23.25 10.55 256.68 
11 38.624 49.09 21.45 2.44 > 191 
12 4.238 > 62 73.77 2.17 102.34 
a
 T. b. rhodesiense STIB900 trypomastigotes; 
b
 T. cruzi Tulahuen strain C2C4 471 
trypomastigotes; 
c 
L. donovani strain MHOM/ET/67/L82 axenically grown amastigotes; 
d 
P. 472 
falciparum K1 erythrocytic stages; 
e
 Rat skeletal myoblast L-6 cells; 
f
 selectivity index = 473 
[IC50 (L6-cells) / IC50 (parasite)]; 
g
 The chloroquine-sensitive strain of P. falciparum NF54 474 
shows an IC-50 value of 0.0077 µM in this assay. 475 
 476 
 477 
 478 
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Table 2. In vitro activity of alkyl mono- and bis-guanidinium compounds against P. 479 
falciparum K1.  480 
 481 
Compound R1 Linker P. falciparum 
 
  IC-50 (µM) (SI)a 
Cytotoxicity L6 
IC-50 (µM) 
5e -(CH2)6- 0.80 (83) 104.76 
5g -(CH2)8- 0.31 (222) 69.09 
5h  -(CH2)9- 0.17 (558) 94.87 
13 -(CH2)6- 0.445 (>679) >302 
14 -(CH2)8- 0.106 (>2608) >276 
15  -(CH2)9- 0.084 (>3162) >265 
16 CH3 -(CH2)12- 7.98 (2.4) 19.6 
a
 Selectivity index = [IC50(L6 cells)] / [IC50(P. falciparum)] 482 
 483 
